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background: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder associated with cardiovascular disease
(CVD) risk factors and metabolic disturbances. This systematic review and meta-analysis was conducted to determine whether carotid
intima-media thickness (CIMT), a marker of subclinical atherosclerosis, is higher in women with PCOS compared with women without
PCOS.
methods: Primary articles reporting the mean CIMT in women with PCOS and controls were identified using Ovid MEDLINE, EMBASE
and PUBMED. We performed a random-effects meta-analysis and created forest plots of the mean difference in CIMT and conducted tests
for heterogeneity and publication bias. Studies were grouped by quality, defined by reporting reproducibility of CIMT and averaging both
common carotid arteries versus one side for CIMT.
results: From the 36 eligible full-text studies, 8 studies were included in the systematic review and 19 studies were included in the meta-
analysis (total n ¼ 1123 women with PCOS, n ¼ 923 controls). The summary mean difference in CIMT among women with PCOS compared
with controls was 0.072 mm [95% confidence interval (CI) 0.040, 0.105, P , 0.0001] for highest quality studies, 0.084 mm (95% CI 0.042,
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0.126, P ¼ 0.0001) for good quality studies, 0.041 (95% CI 20.038, 0.120, P ¼ 0.310) for fair-quality studies and 0.045 (95% CI 20.020,
0.111, P ¼ 0.173) for lower quality studies.
conclusions: Larger studies with a well-defined PCOS population using rigorous methodology may be required to draw a more robust
conclusion. However, these results suggest women with PCOS are at a greater risk of premature atherosclerosis, which emphasizes the
importance of screening and monitoring CVD risk factors in women with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is a reproductive endocrine dis-
order that affects 7 million women or 6–10% of women in
the USA (Azziz et al., 2004; Nestler, 2008). Women with PCOS ex-
perience acne, excessive hair, weight gain and irregular periods. In
addition, these women also have an increase in cardiovascular
disease (CVD) risk factors with more insulin resistance (IR)
(Glueck et al., 2009), dyslipidemia (Legro et al., 2001), abdominal
obesity (Cascella et al., 2008), type 2 diabetes (Moran et al., 2010)
and inflammation (Boulman et al., 2004) than those without this dis-
order. These risk factors and metabolic disturbances may be asso-
ciated with functional and structural impairments of the vascular
system resulting in acceleration of atherosclerosis as these
women age.
The extent to which there is an increased risk of subclinical
atherosclerosis and CVD events among women with PCOS remains
controversial. Studies of CVD events in women with PCOS are
limited but a recent meta-analysis showed women with PCOS had
two times the relative risk of coronary heart disease or stroke than
controls (de Groot et al., 2011). Some studies have found that
women with PCOS had more severe subclinical atherosclerosis as
measured by coronary calcification scores (CAC) (Christian et al.,
2003; Talbott et al., 2004, 2008; Shroff et al., 2007), carotid artery
intima-media thickness (CIMT) (Talbott et al., 2000; Lakhani et al.,
2004; Orio et al., 2004; Vryonidou et al., 2005; Vural et al., 2005;
Carmina et al., 2006; Heutling et al., 2008) and endothelial dysfunction
measured by flow-mediated dilation (FMD) (Tarkun et al., 2004;
Kravariti et al., 2005; Lowenstein et al., 2007; Cascella et al., 2008)
compared with controls. However, these studies have not shown
consistent results (Meyer et al., 2005; Costa et al., 2008; Arikan
et al., 2009; Soares et al., 2009). Most of these investigations for
subclinical atherosclerosis were limited by small sample sizes and
evaluated young women of reproductive age.
Several excellent reviews have discussed the association of PCOS
with CVD risk factors and the risk of CVD (Legro, 2003; Loverro,
2004; Cussons et al., 2006; Dokras, 2008; Mak and Dokras, 2009;
Wild et al., 2010) but a systematic review has yet to be conducted
of studies on subclinical atherosclerosis in women with PCOS.
Thus, the aim of this study was to review the literature regarding
CVD risk assessment by CIMT in women with PCOS compared
with controls. CIMT is a non-invasive ultrasound measure of the
thickness of the intima-media of the common carotid arteries.
CIMT is a widely used structural marker of subclinical atherosclerosis
that is associated with CVD risk factors (van der Meer et al., 2003;
Hurst et al., 2007) and CVD events (Poredos, 2004; Espeland
et al., 2005; Lorenz et al., 2007a, b). The protocol for this report
follows the Preferred Reporting Items for Systematic Reviews and




Primary articles investigating CIMT among women with PCOS and without
PCOS (controls) were included if they: (i) were a peer-reviewed primary
article, (ii) had a study population of women with PCOS [diagnostic cri-
teria for PCOS specified by the National Institutes of Health (NIH)]
(Zawadzki and Dunaif, 1992), the European Society of Human Reproduc-
tion and Embryology/American Society of Reproductive Medicine
(ESHRE/ASRM, 2004) and/or the Androgen Excess Society (AES) criteria
(Azziz et al., 2006), and were compared with controls without PCOS, (iii)
reported a measure of CIMT (unadjusted or adjusted) and (iv) were pub-
lished in the English language. Studies without a control group were
excluded.
Search strategy and study selection
Articles assessing CIMT in women with PCOS were identified using Ovid
MEDLINE, EMBASE and PUBMED. The primary search was conducted in
Ovid MEDLINE through 19 November 2010 (M.L.M.). The search terms
for Ovid MEDLINE included carotid artery diseases, tunica media, carotid
artery, common/tunica intima, arteriosclerosis, intima-media thickness
and PCOS: physiopathology, pathology, complications, etiology, mortality,
ultrasonography, epidemiology, prevention and control (Fig. 1). The
search terms for EMBASE were intima-media thickness, ovary polycystic
disease limited to humans and limited to the publication years to 1980–
2010. A search from 1980 to 2010 through PUBMED did not identify
any new references. Two independent investigators reviewed reference
lists from the primary search (M.L.M. and E.O.T.). Review papers were
assessed to find possible references not identified in the Medline and
EMBASE journal databases. Before finalizing this meta-analysis, a
PUBMED search in February 2011 identified an additional study published
in 2011.
Data extraction
The data from the studies were extracted into a table and re-verified
(M.L.M.). The information from each study included: first author,
journal, study design, whether the study controlled for age and BMI or
weight, PCOS diagnostic criteria used, source of the control population,
number of participants, mean age and BMI of the participants, measure
of CIMT (both unadjusted and adjusted measures were extracted if
reported), P-value for the difference between cases and controls and
the methodology for the CIMT measurement (carotid segments used,
the calculation of CIMT and reproducibility information).
Two investigators met to discuss the eligibility of studies to be included
in the meta-analysis (M.L.M. and E.O.T.). In cases of disagreement, a third
Polycystic ovary syndrome and atherosclerosis 113
arbitrator was consulted (R.A.W.). Two of the three investigators were
required to be in agreement. After reviewing articles, 26 studies met
the inclusion criteria and 19 studies were suitable for the meta-analysis
(Fig. 2). One article published in 2011, as mentioned previously, was
added to the meta-analysis (Pepene et al., 2011). For the statistical ana-
lysis, three studies were excluded that did not report necessary informa-
tion for the meta-analysis (Meyer et al., 2005; Vryonidou et al., 2005;
Pamuk et al., 2010), one paper for reporting unusual CIMT values (Adali
et al., 2010) and four papers that were from the same author or study
population (Guzick et al., 1996; Carmina et al., 2006; Cascella et al.,
2006; Erdogan et al., 2008). In instances of duplicate papers from the
same first author, the most recent study containing the larger sample
size was included in the meta-analysis.
Assessment of risk of bias
Two investigators independently assessed limitations and possible biases
within each study (M.L.M. and E.O.T.). This information was used to de-
termine whether studies were adequate for the meta-analysis and to de-
termine possible sources of heterogeneity. A priori, it was hypothesized
that the studies might differ according to the protocol and reproducibility
of CIMT and the PCOS diagnostic criteria that was used. Publication bias
across studies was assessed using a funnel plot and Egger’s test.
Data analysis
The primary outcome of interest was the mean difference in CIMT
between women with PCOS and women without PCOS. The
Figure 1 Diagram of the search strategy used to identify articles for a systematic literature review of CIMT in women with PCOS and controls.
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meta-analysis was performed using a random-effects model to compute
the mean difference in CIMT and the 95% confidence intervals (CIs) for
each study and an overall summary estimate. The mean CIMT, the SD
and the sample size were available for most of the studies. Four
studies were included that reported means and exact P-values (Talbott
et al., 2000; Alexandraki et al., 2006; Pepene et al., 2011), and three
studies were included that used an adjusted mean CIMT (Talbott
et al., 2000; Lakhani et al., 2004; Orio et al., 2004). Two studies were
included two times because the case–control groups were stratified by
age (Talbott et al., 2000) and obesity (Ketel et al., 2010). The
numbers in the manuscript reflect those studies being included as one,
instead of two.
Three studies were ineligible to be included for the meta-analysis
because they did not report the necessary information (Meyer et al.,
2005; Vryonidou et al., 2005; Pamuk et al., 2010). One study was excluded
because the reported CIMT was unusually low in both women with PCOS
and controls (Adali et al., 2010). One study stratified cases by levels of the
homeostasis model assessment-IR (HOMA) but not the control group
(Karadeniz et al., 2008). For this study, the CIMT from the case group
that was most similar to controls was used to give a conservative estimate.
The results for right CIMT were used for three studies that reported the
left and right CIMT separately (Karadeniz et al., 2008; Trakakis et al., 2008;
Erdogan et al., 2009).
Forest plots were created with the random-effect model to obtain an
estimate of the overall mean difference in CIMT across the studies. The
random-effects model was used to incorporate greater variability or het-
erogeneity between the studies. The a priori hypothesis was that the het-
erogeneity may be related to differences in PCOS diagnostic criteria, the
age and BMI of the study populations, the protocol for CIMT and the ob-
server variation of the technician(s) performing the ultrasound
Figure 2 PRISMA 2009 flow diagram.
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assessments. Beyond visual assessment for heterogeneity, homogeneity
was tested using the x2 test Cochran’s Q-statistic. A P , 0.10 was used
to suggest heterogeneity. The I2 statistic was computed to measure the
proportion of inconsistency that could not be explained by chance in
each of the individual studies (Higgins et al., 2003). I2 ranges between 0
and 100% with lower values representing less heterogeneity. The recom-
mended guidelines for low, moderate and high I2 values are ,25, 50 and
.75%, respectfully (Higgins et al., 2003). However, the power to detect
bias is under 0.80 with a meta-analysis of less than 20 studies and including
studies with less than 80 participants (Hardy and Thompson, 1998; Gava-
ghan et al., 2000; Huedo-Medina et al., 2006).
To examine possible sources of heterogeneity between studies, the
meta-analysis was conducted by grouping the studies by the quality of
the CIMT measurement. The quality of the studies was determined by
evaluating if the study reported reproducibility of CIMT and if the study
used an average of the left and right common carotid artery (CCA) for
CIMT versus just one side. This criterion was used because the average
of measures from the left and right CCA would be more stable than
the average of one side (Thompson et al., 2001). Finally, to assess possible
publication bias, a funnel plot was created to assess for symmetry and
the Egger regression test was performed to test for asymmetry of the
funnel plot. The Egger test evaluates the association between the
standardized effect estimate (estimate divided by SE) and the precision
(1/SE) through the use of linear regression for Y-intercept ¼ 0 (Egger
et al., 1997). All analyses were performed using Comprehensive
Meta-Analysis software [Borenstein M, Hedges L, Higgins J, Rothstein




A total of 56 articles were identified for the review through a database
search of Ovid MEDLINE and EMBASE after adjusting for duplicates
(Fig. 2). The investigator screened the title and abstracts and excluded
20 articles because they were reviews, did not have a control group or
did not report a CIMT measurement. There were 36 full-text studies
that met the eligibility criteria for this systematic review and
meta-analysis. Of these, 10 studies were excluded because they
were not in English, did not have a control group or did not report
a CIMT value. Eight studies were excluded from the meta-analysis
because they had the same first author or study population, the neces-
sary statistics were not reported or the CIMT values were abnormal
compared with the other studies, as previously mentioned. In
summary, the search identified 8 studies for the systematic review
and 18 studies for the meta-analysis. An additional article published
in 2011 was identified and subsequently added to the meta-analysis,
for a total of 19 studies to be included in the meta-analysis.
The 8 studies in the qualitative systematic review and the 19 studies
in the meta-analysis were cross-sectional studies with the exception of
one RCT (Heutling et al., 2008). Eight studies were included in the
qualitative review (Table I). As previously mentioned, these studies
had either a duplicate study population as a study included in the
meta-analysis or incomplete statistics for the meta-analysis. This ana-
lysis focused on the 19 studies that were included in the meta-analysis
(Table II). The 19 studies in the meta-analysis involved a total of 1123
women with PCOS and 923 non-PCOS controls. The sample sizes
ranged from 18 to 200 women with PCOS and from 12 to 142
controls. Women with PCOS were diagnosed using the NIH criteria,
the AES criteria or the Rotterdam criteria. The studies enrolled
patients (Karadeniz et al., 2008; Soares et al., 2009), community con-
trols (Guzick et al., 1996; Talbott et al., 2000; Heutling et al., 2008)
and doctors, medical students and nurses as controls (Lakhani et al.,
2004; Vural et al., 2005; Alexandraki et al., 2006; Saha et al., 2008;
Trakakis et al., 2008; Arikan et al., 2009). Some studies did not
specify where the healthy controls came from or how they were
recruited (Orio et al., 2004; Carmina et al., 2006; Cascella et al.,
2006; Luque-Ramirez et al., 2007; Costa et al., 2008; Erdogan et al.,
2008; Ciccone et al., 2009; Pepene et al., 2011).
The studies enrolled women with a mean age range from 22 to 40
years and a mean BMI range from 21 to 30 kg/m2. The women were
premenopausal with the exception of one study (Talbott et al., 2000).
All but four studies matched or adjusted for age and BMI or weight
between women with PCOS and controls for the CIMT estimate
(Vural et al., 2005; Saha et al., 2008; Ciccone et al., 2009; Pepene
et al., 2011). CIMT was assessed using B-mode ultrasound of the
CCA and calculated as a mean of measurements of the far wall of
the left and right CCA. One study used the maximum CIMT
(Pepene et al., 2011). Most studies averaged the right and left CCA
together, whereas a few reported them separately. The mean CIMT
ranged from 0.41 to 0.75 mm in women with PCOS and from 0.33
to 0.74 mm in controls.
Quality control measures for CIMT were reported in nine studies.
The most common reported reproducibility statistic was the
intra-observer coefficient of variation (CV). The CV shows the vari-
ability between measures, where low CV values indicate less variability
in the measures. The intra-observer CV for seven studies were ,11%
(Lakhani et al., 2004; Orio et al., 2004; Luque-Ramirez et al., 2007;
Cascella et al., 2008; Heutling et al., 2008; Carmina et al., 2009b;
Pepene et al., 2011), and the inter-observer CV for one study was
12% (Orio et al., 2004). One study reported an intra-class correlation
coefficient of 0.86 (Talbott et al., 2000), where higher values indicate
more measurement variability related to differences between patients
rather than other sources of error. One study reported an
intra-observer error of ,0.03 mm (Vural et al., 2005). The other
10 studies did not mention the quality control measures for CIMT
(Karadeniz et al., 2008; Saha et al., 2008; Trakakis et al., 2008;
Erdogan et al., 2009; Soares et al., 2009; Ketel et al., 2010). But,
five of these studies indicated that there was one technician reading
the CIMT images (Alexandraki et al., 2006; Costa et al., 2008;
Arikan et al., 2009; Ciccone et al., 2009).
From this information, the studies were ranked by the quality of the
CIMT assessment. There were seven studies considered to be of the
highest quality because they reported a reproducibility statistic and
used the left and right CCA for CIMT (Talbott et al., 2000; Orio
et al., 2004; Vural et al., 2005; Cascella et al., 2008; Heutling et al.,
2008; Carmina et al., 2009b; Pepene et al., 2011). Two studies
were considered of good quality because they reported a reproduci-
bility statistic and used one CCA for CIMT (Lakhani et al., 2004;
Luque-Ramirez et al., 2007). Five studies were considered to be of
fair quality because they did not report a reproducibility statistic and
used the left and right CCA for CIMT (Alexandraki et al., 2006;
Costa et al., 2008; Saha et al., 2008; Arikan et al., 2009; Ciccone
et al., 2009). The remaining five studies were considered lower
quality because they did not report a reproducibility statistic and
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Community Age 16 casesa 44.4+0.9c 32.7+2.3c 0.680+0.019c P ¼ 0.035 CCA, Bif, ICA Mean, left and right,
near and far wall
CCA, far wall bulb
and ICA
Same population as
Talbott et al. (2000)16 controls 43.9+1.3c 25.3+1.2c 0.630+0.012c
Meyer et al.
(2005)
Community NA 100 casesa 32.7+1.8c 37.3+2.43c 0.55+0.01c P . 0.05 CCA Mean, right, far wall Did not report







Age and BMI 75 casesa 23.9+5.4 27.3+7.0 0.58 (0.42–
0.80)d
P , 0.001 CCA Mean and max, left
and right, far wall
Did not report
necessary statistics




NA Age and weight 50 casesa 25.2+1c 28.7+0.8c 0.50+0.01c P , 0.01 CCA Mean, left and right,
near and far walls
Included Carmina
et al. (2009a,b)50 controls 25.1+0.7c 28.5+0.5c 0.41+0.01c
Cascella
et al. (2006)
NA Age and BMI 50 casesb 21.9+2.7 24.6+2.5 0.50+0.07 P , 0.001 CCA Mean, left and right,
far wall
Included Cascella
et al. (2008)50 controls 22.2+2.8 24.4+2.8 0.40+0.05
Erdogan
et al. (2008)
NA NA 68 casesb 24.3+5.4 24.4+5.4 Right CIMT
0.42+0.5











Outpatient clinic Age 24 overweight
or obese
casesb

























NA, not addressed; CCA; common carotid artery; Bif, carotid bifurcation; ICA, internal carotid artery; P values are cases versus controls.
aNIH PCOS Criteria.
bRotterdam PCOS Criteria.
cData expressed as SE.






















Community Age and BMI 125 casesa 37.5+6.2c 30.1+0.7c Age-BMI adjusted (CI) CCA, Bif, ICA Mean, left and right,
































Staff members Age 19 PCOSb 29.2+4.0 31.3+8.2 0.54+0.11 0.53+0.09d P ¼ 0.006,
P ¼ 0.034d






12 PCO 27.7+4.0 22.5+3.8 0.51+0.18 0.50+0.15d P ¼ 0.038,
P ¼ 0.841dCI (0.81–
0.7)
12 controls 27.5+4.0 24.2+3.4 0.40+0.09 0.44+0.09d









Age 43 casesb 21.4+1.8 23.4+4.7 0.75+0.11 P , 0.001 CCA Left and right, near and
far walls, intra-observer
error ,0.03 mm





Age and BMI 27 casesa 25.4+0.8c 27.42+1.1c 0.49+0.01c P ¼ 0.19 CCA, Bif, ICA Mean, left and right, far






40 casesa 24.5+5.8 29.4+6.3 0.41+0.11 P ¼ 0.005 CCA Left, far wall,
intra-observer CV
10.8%
20 controls 27.2+6.8 28.2+6.9 0.33+0.08
Cascella et al.
(2008)
NA Age and BMI 200 casesb 24.6+3.2 28.5+2.8 0.46+0.16 P , 0.001 CCA Mean, left and right, far
wall, intra-observer CV
7.0%
100 controls 24.0+2.8 28.8+2.7 0.38+0.09
Costa et al.
(2008)
NA 57 casesb 25.5+5.3 27.6+5.8 0.52+0.08 P ¼ 0.35 CCA Mean, left and right, far
wall, one reader37 controls 26.6+5.4 26.7+4.9 0.53+0.08
Heutling et al.
(2008)*
Public advertising 83 casesb 24.8+4.7 30.4+5.9 0.48+0.07 P , 0.001 CCA Mean, left and right, far
wall, intra-observer CV
6.8%











23.8+5.5 25.6+5.6 Right: 0.41+0.05 P . 0.05 CCA NA




24.9+5.1 22.2+4.1 Right: 0.43+0.05 P . 0.05
Left: 0.45+0.06 P . 0.05
25 controls 27.2+4.2 23.4+5.2 Right: 0.44+0.05
Left: 0.44+0.05
Saha et al. (2008) Staff members 30 casesa 26.1+4.2 25.8+4.6 0.63+0.19 P , 0.001 CCA, Bif, ICA Mean, left and right, NS





53 casesb 26.1+5.5 28.7+7.1 Right: 0.67+0.15 P , 0.0001 CCA, ICA Mean CIMT, left and
right, near and far wallLeft: 0.68+0.13 P , 0.0001






Age and BMI 39 casesb 22.8+5.5 21.5+6.5 0.45+0.82 P . 0.05 CCA Mean, left and right, far





Age and weight 95 casesf 24.2+3.0 27.6+5.8 0.61+0.18 P , 0.01 CCA Mean average of 10
measurements of left
and right far wall,
intra-observer CV
,7.0%
90 controls 23.9+3.0 27.5+3.0 0.53+0.15
Ciccone et al.
(2009)
NA Age 29 casesb 22.0+3.8 26.3+4.5 0.651+0.59 P . 0.05 CCA, ICA, Bif Mean of average of
three measures from
right and left, plaque
free segments, one
technician
26 controls 22.0+3.8 20.5+1.6 0.637+0.133
Soares et al.
(2009)
Basic health clinic Age and BMI 40 casesb 24.5+3.8 22.7+3.3 0.44+0.10 P ¼ 0.41 CCA Mean of average of four
measures of right CCA50 controls 24.5+5.1 23.1+3.2 0.42+0.09
Erdogan et al.
(2009)
Outpatient clinic Age and BMI 88 casesb 24.1+1.3 24.4+4.1 Right: 0.74+0.59 P . 0.05 CCA NA
Left: 0.73+0.80






Age and weight 22 lean casesb 28.6+4.5 22.0+2.2 0.53+0.08 P . 0.05 CCA Right side, mean of
three measurements18 obese casesb 30.3+4.2 36.2+5.9 0.56+0.17
17 lean controls 27.7+5.3 22.2+1.7 0.48+0.07
13 obese controls 28.6+5.3 40.5+7.0 0.60+0.11
Pepene et al.
(2011)
NA Age 64 casesf 28.6+5.4c 29.9+0.8c 0.572+0.017c P ¼ 0.323 CCA, Bif, ICA Single max CIMT, left
and right, one tech, CV
5%
20 controls 28.6+5.5c 26.3+1.3c 0.635+0.062c
RCT; randomized control trail; NA, not addressed.
aNIH PCOS criteria.
bRotterdam PCOS criteria.
cData expressed as SE.
dCIMT adjusted for age, systolic blood pressure (SBP), diastolic blood pressure (DBP), BMI, cholesterol and insulin.
eAdjusted for age, BMI, waist to hip ratio, smoking status, glucose and insulin levels, free androgen index, lipid profile, homocysteine concentrations and SBP and DBP;
fAndrogen Excess Society (AES) PCOS criteria.








used one CCA for CIMT (Karadeniz et al., 2008; Trakakis et al., 2008;
Erdogan et al., 2009; Soares et al., 2009; Ketel et al., 2010). (Two
studies Talbott et al., 2000; Ketel et al., 2010 were included two
times because the case–control groups were stratified by age or
obesity. The numbers in the manuscript reflect those studies being
included as one, instead of two.)
Risk of bias
The funnel plot of the seven high-quality studies suggested no evidence
of publication bias because the studies were symmetrical around the
mean and the Egger’s regression test was not significant at P ¼ 0.94
(data not shown). Publication bias was not assessed among the two
good quality studies as this requires more than three studies to run
publication bias procedures. The funnel plots of the fair- and low-
quality studies were also symmetrical around the mean (data not
shown) and the Egger’s test P-value was 0.48 for the five studies
without reproducibility and used the right and left CCA, and the
P-value was 0.61 for the five studies without reproducibility and
used one CCA.
Mean difference in CIMT
The forest plots showed that the mean difference in CIMT between
women with PCOS and controls varies across the groups of studies
(Figs 3 and 4, Table III). The forest plot of the seven high-quality
studies suggested that the cases had a greater CIMT than controls
as most of the estimated difference in means, except one, were to
the right of zero (Fig. 3a). The widths of the 95% CIs were similar,
which indicated that the studies had similar precision in the estimates.
The summary random-effect mean difference in CIMT showed that
women with PCOS had a significantly greater CIMT than controls
(0.072, 95% CI 0.040, 0.105, P , 0.0001). The Q-statistic for hetero-
geneity was significant (x2¼ 36.82, P , 0.0001, I2¼ 80.99).
Like the previous studies, the forest plot of the two good quality
studies showed that the estimated difference in means and 95% CIs
were similar and were located to the right of zero (Fig. 3b). The
summary random-effect mean difference in CIMT showed that
women with PCOS had a significantly greater CIMT than controls
(0.084, 95% CI 0.042, 0.126, P , 0.0001). The Q-statistic for hetero-
geneity was not significant (x2¼ 0.05, P ¼ 0.82, I2¼ 0.00). However,
as noted earlier, heterogeneity estimates should be interpreted with
caution because they are not reliable with a small number of studies
and small numbers of participants within some studies.
The forest plot of the five fair-quality studies showed that most of
the estimates and 95% CIs cross zero, except for one study
(Fig. 4a). Two studies had a wide CI compared with the rest, which
indicated less precision in the estimate. In contrast to the high-quality
studies, the estimates of the difference in CIMT across studies did not
show a consistent pattern. The summary random-effect mean differ-
ence in CIMT was not significant between women with PCOS and
controls (0.041, 95% CI 20.038, 0.120, P ¼ 0.310), and the
Q-statistic for heterogeneity was significant (x2¼ 30.11, P , 0.0001,
I2¼ 86.72).
Similar to the fair-quality studies, the forest plot of the five low-
quality studies showed that most of the estimates were around zero
and the 95% CIs crossed zero, except for one study (Fig. 4b).
Similar to the fair-quality studies, there was not a consistent pattern
in the estimated difference in means and CIs across studies. The
summary random-effect mean difference in CIMT was not significant
between women with PCOS and controls (0.045, 95% CI 20.020,
0.111, P ¼ 0.173), and the Q-statistic for heterogeneity was significant
(x2¼ 43.58, P , 0.0001, I2¼ 88.53).
Discussion
Summary of evidence
This meta-analysis demonstrates that women with PCOS have a higher
mean CIMT compared with non-PCOS controls. The summary esti-
mate of the mean difference in CIMT was 0.072 mm for women with
PCOS compared with controls (95% CI 0.040–0.105, P , 0.0001)
for the high quality and was similar to the good quality studies
(0.084 mm, 95% CI 0.042, 0.126, P ¼ 0.0001). The summary estimate
of the difference in CIMT for the fair- and low-quality studies was higher
among women with PCOS but was not significantly different, P . 0.05.
The average change in CIMT for women is estimated to be around 0.009
(Chambless et al., 2002) and 0.015 mm per year (Johnson et al., 2007),
thus the summary mean difference corresponds to about a 7 year pro-
gression in CIMT. This difference in CIMT was detected despite includ-
ing small studies of young women.
These results should be viewed in light of the significant heterogen-
eity across studies. As previously mentioned, these tests may have had
low power. Nonetheless, heterogeneity could be related to between
the study differences in PCOS phenotypes, age, BMI, CVD risk factors
and technical factors related to assessment of CIMT. Larger studies
with a well-defined PCOS population using rigorous methodology
may be required to draw a more robust conclusion. However, the evi-
dence to date suggests women with PCOS are at risk for premature
atherosclerosis. This emphasizes the importance of screening for
and addressing CVD risk factors as a way of reducing progression of
CVD in this high-risk subgroup.
Strengths and limitations of the review
The limits of the search and the inclusion of studies only in the English
language may have introduced possible publication bias in the
meta-analysis. However, only three non-English studies were excluded
and we did not detect evidence of publication bias from the funnel
plots or Egger’s test. Another limitation was the heterogeneity that
suggested the populations and CIMT measurements were not the
same across studies. The heterogeneity was addressed by using the
random-effects model and grouping the studies according to quality
of the CIMT measurement.
CIMT is a reproducible measure but has within and between
study variability owing to random error and error from study partici-
pants and technicians. Larger variability of CIMT would decrease the
reproducibility and require larger sample sizes to maintain adequate
power. The subgroup analysis showed that the consistency of the esti-
mates across studies increased as the quality of the CIMT measure-
ment increased. The high-quality studies had consistent CIMT
estimates across studies and a more robust summary estimate. This
is in contrast to the fair- and low-quality studies in which the estimates
had more variation across studies. There were a few estimates with a
wide CI that suggested lower precision in the estimate, and the
summary estimate was much weaker and not significant at P , 0.05.
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These observations demonstrate the importance of reporting quality
control measures and describing the protocol and reproducibility of
CIMT. A large portion of the studies did not describe quality
control measures for the CIMT measurement (Alexandraki et al.,
2006; Costa et al., 2008; Karadeniz et al., 2008; Saha et al., 2008; Tra-
kakis et al., 2008; Arikan et al., 2009; Ciccone et al., 2009; Erdogan
et al., 2009; Soares et al., 2009; Ketel et al., 2010).
Heterogeneity between studies could also be caused by differences
in the prevalence of CVD risk factors and PCOS phenotypes. The Rot-
terdam criteria add an additional, less severe, phenotype to the diag-
nosis, which could increase heterogeneity and may lower the power of
a study to detect a difference between participants with and without
PCOS. There is evidence that the prevalence of CVD risk factors
varies by PCOS phenotype (Jovanovic et al., 2010). Women with
the classical definition of PCOS had a higher prevalence of one or
more CVD risk factors, which include C-reactive protein (CRP),
lipids and homocysteine, than ovulatory women with PCOS
(Carmina et al., 2005). Women with classical PCOS also had more ab-
dominal obesity than ovulatory women with PCOS with similar BMI
(P , 0.05) (Carmina et al., 2009a). On the other hand, non-
hyperandrogenic women with PCOS that are included in the Rotter-
dam criteria and not the NIH criteria had normal androgen levels
and lower prevalence of IR and metabolic abnormalities than
women with classical or ovulatory PCOS (Chae et al., 2008).
This meta-analysis is also vulnerable to limitations within each study
that include their cross-sectional study designs and small sample sizes.
Smaller studies may have lacked sufficient power to detect a difference
in CIMT between cases and controls as the sample sizes of the studies
ranged from 18 to 200 women with PCOS and 12–142 controls.
Another limitation was the potential selection bias within the
studies. The response rate of recruitment was not reported in any
of the studies, which may lead to potential selection bias. In addition,
Figure 3 (A) Boxes represent the estimated difference in mean CIMT and lines indicate the 95% CI. (B) Boxes represent the estimated difference in
mean CIMT and lines indicate the 95% CI.
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there were differences in the average age and BMI between women
with PCOS and controls in some studies, but this was controlled for
in all of the studies except three (Vural et al., 2005; Saha et al.,
2008; Ciccone et al., 2009). Exclusion of these three studies from
the analysis did not change the results.
The strength of this paper is that the meta-analysis was able to sum-
marize results from the conflicting body of literature and increase stat-
istical power by estimating a summary effect for the studies limited by
small sample size. Also, grouping studies by the quality of the CIMT
measurement identified potential sources of heterogeneity and
demonstrated the robustness of the results. This is the first
meta-analysis to investigate differences in CIMT between women
with PCOS and controls, and showed the presence of more pro-
nounced subclinical atherosclerosis in women with PCOS.
Comparison with previous research
Overall, the results indicated that women with PCOS had a 0.072–
0.084 mm higher CIMT compared with controls. This is similar to
studies of subclinical atherosclerosis as measured by CAC and FMD
among women with PCOS. Women with PCOS had a higher preva-
lence of CAC defined by none versus any (Christian et al., 2003;
Talbott et al., 2004; Shroff et al., 2007), and more CAC defined by
an Agatston score of ,10 versus ≥10 (Talbott et al., 2008) and sig-
nificantly lower FMD (Kravariti et al., 2005; Meyer et al., 2005;
Carmina et al., 2006; Cascella et al., 2008) when compared with
controls.
There are several mechanisms that may explain the increase in
CIMT among women with PCOS. Higher levels of circulating insulin
(Carmina et al., 2009b), total cholesterol and low-density lipoprotein
Figure 4 (A) Boxes represent the estimated difference in mean CIMT and lines indicate the 95% CI. (B) Boxes represent the estimated difference in
mean CIMT and lines indicate the 95% CI.
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cholesterol (Alexandraki et al., 2006; Saha et al., 2008), triglycerides
(Saha et al., 2008), CRP (Cascella et al., 2008), serum interleukin-18
(Kaya et al., 2010), lower levels of high-density lipoprotein cholesterol
(Vryonidou et al., 2005) and abdominal obesity (Cascella et al., 2008;
Carmina et al., 2009b) were each associated with CIMT in women
with PCOS. This analysis showed women with PCOS have greater
CIMT than controls, but we could not evaluate the influence of
CVD risk factors that are strongly associated with PCOS and CIMT,
given the design of this meta-analysis. Women with PCOS had
higher insulin levels or IR compared with controls in all studies
included in the meta-analysis except four (Lakhani et al., 2004; Alex-
andraki et al., 2006; Arikan et al., 2009; Soares et al., 2009). Further
classification of PCOS phenotypes and CVD risk factors in PCOS is
needed to understand the complexity of PCOS and the risk of CVD.
Clinical implications
This meta-analysis suggests that women with PCOS have more early
adverse structural changes in the vascular system than normal men-
struating women, having about a 0.08 mm greater CIMT, indicating
an increased risk of a cardiovascular event. To put the results in per-
spective, every 0.10 mm increase in CIMT has been estimated to in-
crease the risk of a myocardial infarction (MI) by 15% and the risk
of stroke by18% (Lorenz et al., 2007b). Other reports show for
every 0.16 mm increase in CIMT, the risk of an MI, stroke or death
increases by 24% (Staub et al., 2006) and by 19% after adjusting for
age and sex (Lorenz et al., 2006).
The increase in subclinical CVD suggests that primary CVD preven-
tion would be beneficial for women with PCOS. CIMT could be used
for risk stratification to identify women who are at the highest risk for
CVD and who would benefit from an intervention or advanced
therapy. CIMT can be reduced and progression can be slowed with
diet alone (Markus et al., 1997), or combined with lifestyle interven-
tions (Wildman et al., 2004), or with the use of metformin (Heutling
et al., 2008) or cholesterol-lowering medications (Probstfield et al.,
1995).
It is important to monitor women with PCOS as they age and tran-
sition through menopause. Post-menopausal women have higher
CIMT (Sutton-Tyrrell et al., 1998) and greater CIMT progression
(Wildman et al., 2004) compared with premenopausal women. All
studies except one included in this analysis enrolled premenopausal
women. Our results show that women with PCOS have more subclin-
ical CVD before menopause that is likely to progress and develop to
more advanced CVD with age compared with women without PCOS.
Conclusions
The findings from this meta-analysis on subclinical atherosclerosis in
women with PCOS demonstrated higher CIMT in women with
PCOS than that in controls. Heterogeneity was observed across
studies, which may be related to that fact that PCOS is a complex het-
erogeneous syndrome associated with CVD risk factors. The results
showed greater variation in the CIMT estimates across studies as
the quality of the CIMT measurement decreased, which may partially
explain inconsistencies in the literature. This can be improved by using
standardized ultrasound protocols and reporting detailed methods for
CIMT.
Identifying PCOS as a risk factor for CVD is difficult given the young
age of onset of PCOS with CVD events that tend to occur with aging.
To date, most studies have been conducted in young women but the
risk of CVD may not be evident until later in life. Large prospective
studies with detailed PCOS phenotypic data and change in subclinical
atherosclerosis are needed to provide a better estimate of the risk of
CVD in women with PCOS.
In the absence of these studies, PCOS is accompanied by CVD risk
factors that put these women at an increased risk of atherosclerosis.
These findings support recommendations for screening and monitor-
ing CVD risk factors in women with PCOS, as endorsed by the Andro-
gen Excess and PCOS society (Wild et al., 2010). This is of important
public health significance as it will allow for the early identification of
...............................
.............................................................................................................................................................................................
Table III PCOS and CIMT meta-analysis results for random-effects models by quality of CIMT measurement.




SE 95% CI P-value Heterogeneity
x2 (P-value)a I2
1 Studies reporting reproducibility and using right
and left CCA for CIMT
8b 0.072 0.017 0.040, 0.105 ,0.0001 36.818
(,0.0001)
80.988
2 Studies reporting reproducibility and using one
CCA for CIMT
2 0.084 0.021 0.042, 0.126 ,0.0001 0.054 (0.817) 0
3 Studies not reporting reproducibility and using
right and left CCA for CIMT
5 0.041 0.040 20.038, 0.120 0.3098 30.113
(,0.0001)
86.717
4 Studies not reporting reproducibility and using
one CCA for CIMT
6c 0.045 0.033 20.020, 0.111 0.1734 43.575
(,0.0001)
88.526




ax2 from Q-value based on fixed effects model.
bTalbott et al. (2000) included two subgroups.
cKetel et al. (2010) included two subgroups.
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hypertension, type 2 diabetes and premature atherosclerosis in this
high-risk population.
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